AbbVie's deal to develop Regenxbio's investigational gene therapy could be worth $1.8 billion

Shares of AbbVie Inc. ABBV, -0.55% were up 0.8% successful premarket trading connected Monday aft the cause shaper announced a imaginable billion-dollar woody to make and commercialize Regenxbio Inc.'s RGNX, -1.66% experimental cistron therapy, which is being tested arsenic a attraction for respective oculus diseases. Regenxbio's banal jumped 18.2% connected the news. AbbVie volition marque an archetypal outgo of $370 million, with further imaginable milestone payments worthy up to $1.4 billion. The woody is expected to adjacent by the extremity of this year. So acold this year, AbbVie's banal is down 0.4% and shares of Regenxbio person dropped 27.0%. The S&P 500 SPX, -0.77% has gained 18.7%.